Yayın:
A colorimetric immunoassay for the detection of human vascular endothelial growth factor 165 (VEGF165) based on anti-VEGF-iron oxide nanoparticle conjugation

dc.contributor.authorCeylan, Hülya Kuduğ
dc.contributor.authorKırbay, Fatma Öztürk
dc.contributor.authorYazgan, İdris
dc.contributor.authorElibol, Murat
dc.date.accessioned2026-01-04T20:05:51Z
dc.date.issued2024-02-14
dc.description.abstractAbstractVascular endothelial growth factor (VEGF) is an indispensable element in many physiological processes, while alterations in its level in the circulating system are signs of pathology-associated diseases. Therefore, its precise and selective detection is critical for clinical applications to monitor the progression of the pathology. In this study, an optical immunoassay biosensor was developed as a model study for detecting recombinant VEGF165. The VEGF165 sample was purified from recombinant Kluyveromyces lactis GG799 yeast cells. Indirect ELISA was used during the detection, wherein iron oxide nanoparticles (FeNPs) were utilized to obtain optical signals. The FeNPs were synthesized in the presence of lactose p-amino benzoic acid (LpAB). VEGF165 antibody was conjugated to the LpAB-FeNPs through EDC/NHS chemistry to convert the iron oxide nanoparticles into VEGF165 specific probes. The specificity of the prepared system was tested in the presence of potential serum-based interferents (i.e., glucose, urea, insulin, C-reactive protein, and serum amyloid A), and validation studies were performed in a simulated serum sample. The proposed immunoassay showed a wide detection range (0.5 to 100 ng/mL) with a detection limit of 0.29 ng/mL. These results show that the developed assay could offer a sensitive, simple, specific, reliable, and high-throughput detection platform that can be used in the clinical diagnostics of VEGF. Graphical Abstract
dc.description.urihttps://doi.org/10.1007/s00604-024-06228-0
dc.description.urihttps://pubmed.ncbi.nlm.nih.gov/38353782
dc.description.urihttp://dx.doi.org/10.1007/s00604-024-06228-0
dc.description.urihttps://hdl.handle.net/11454/104841
dc.identifier.doi10.1007/s00604-024-06228-0
dc.identifier.eissn1436-5073
dc.identifier.issn0026-3672
dc.identifier.openairedoi_dedup___::cdf1d29a42425b35d41de6cfb52ee175
dc.identifier.orcid0000-0003-0365-2760
dc.identifier.pubmed38353782
dc.identifier.scopus2-s2.0-85185101323
dc.identifier.urihttps://hdl.handle.net/20.500.12597/41576
dc.identifier.volume191
dc.identifier.wos001161852300002
dc.language.isoeng
dc.publisherSpringer Science and Business Media LLC
dc.relation.ispartofMicrochimica Acta
dc.rightsOPEN
dc.subjectVascular Endothelial Growth Factor A
dc.subjectImmunoassay
dc.subjectOriginal Paper
dc.subjectIndirect Elisa
dc.subjectVascular Endothelial Growth Factors
dc.subjectIron Oxide Nanoparticle
dc.subjectHuman Vascular Endothelial Growth Factor
dc.subjectBenzoic Acid
dc.subjectHumans
dc.subjectColorimetry
dc.subjectMagnetic Iron Oxide Nanoparticles
dc.subjectOptical Detection
dc.titleA colorimetric immunoassay for the detection of human vascular endothelial growth factor 165 (VEGF165) based on anti-VEGF-iron oxide nanoparticle conjugation
dc.typeArticle
dspace.entity.typePublication
local.api.response{"authors":[{"fullName":"Hülya Kuduğ Ceylan","name":"Hülya Kuduğ","surname":"Ceylan","rank":1,"pid":{"id":{"scheme":"orcid","value":"0000-0003-0365-2760"},"provenance":null}},{"fullName":"Fatma Öztürk Kırbay","name":"Fatma Öztürk","surname":"Kırbay","rank":2,"pid":null},{"fullName":"İdris Yazgan","name":"İdris","surname":"Yazgan","rank":3,"pid":null},{"fullName":"Murat Elibol","name":"Murat","surname":"Elibol","rank":4,"pid":null}],"openAccessColor":"hybrid","publiclyFunded":false,"type":"publication","language":{"code":"eng","label":"English"},"countries":null,"subjects":[{"subject":{"scheme":"keyword","value":"Vascular Endothelial Growth Factor A"},"provenance":null},{"subject":{"scheme":"keyword","value":"Immunoassay"},"provenance":null},{"subject":{"scheme":"FOS","value":"0301 basic medicine"},"provenance":null},{"subject":{"scheme":"keyword","value":"Original Paper"},"provenance":null},{"subject":{"scheme":"FOS","value":"0303 health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Indirect Elisa"},"provenance":null},{"subject":{"scheme":"keyword","value":"Vascular Endothelial Growth Factors"},"provenance":null},{"subject":{"scheme":"keyword","value":"Iron Oxide Nanoparticle"},"provenance":null},{"subject":{"scheme":"keyword","value":"Human Vascular Endothelial Growth Factor"},"provenance":null},{"subject":{"scheme":"keyword","value":"Benzoic Acid"},"provenance":null},{"subject":{"scheme":"FOS","value":"03 medical and health sciences"},"provenance":null},{"subject":{"scheme":"keyword","value":"Humans"},"provenance":null},{"subject":{"scheme":"keyword","value":"Colorimetry"},"provenance":null},{"subject":{"scheme":"keyword","value":"Magnetic Iron Oxide Nanoparticles"},"provenance":null},{"subject":{"scheme":"keyword","value":"Optical Detection"},"provenance":null}],"mainTitle":"A colorimetric immunoassay for the detection of human vascular endothelial growth factor 165 (VEGF165) based on anti-VEGF-iron oxide nanoparticle conjugation","subTitle":null,"descriptions":["<jats:title>Abstract</jats:title><jats:p>Vascular endothelial growth factor (VEGF) is an indispensable element in many physiological processes, while alterations in its level in the circulating system are signs of pathology-associated diseases. Therefore, its precise and selective detection is critical for clinical applications to monitor the progression of the pathology. In this study, an optical immunoassay biosensor was developed as a model study for detecting recombinant VEGF<jats:sub>165</jats:sub>. The VEGF<jats:sub>165</jats:sub> sample was purified from recombinant <jats:italic>Kluyveromyces lactis</jats:italic> GG799 yeast cells. Indirect ELISA was used during the detection, wherein iron oxide nanoparticles (FeNPs) were utilized to obtain optical signals. The FeNPs were synthesized in the presence of lactose p-amino benzoic acid (LpAB). VEGF<jats:sub>165</jats:sub> antibody was conjugated to the LpAB-FeNPs through EDC/NHS chemistry to convert the iron oxide nanoparticles into VEGF<jats:sub>165</jats:sub> specific probes. The specificity of the prepared system was tested in the presence of potential serum-based interferents (i.e., glucose, urea, insulin, C-reactive protein, and serum amyloid A), and validation studies were performed in a simulated serum sample. The proposed immunoassay showed a wide detection range (0.5 to 100 ng/mL) with a detection limit of 0.29 ng/mL. These results show that the developed assay could offer a sensitive, simple, specific, reliable, and high-throughput detection platform that can be used in the clinical diagnostics of VEGF.</jats:p> <jats:p><jats:bold>Graphical Abstract</jats:bold></jats:p>"],"publicationDate":"2024-02-14","publisher":"Springer Science and Business Media LLC","embargoEndDate":null,"sources":["Crossref","Mikrochim Acta"],"formats":null,"contributors":null,"coverages":null,"bestAccessRight":{"code":"c_abf2","label":"OPEN","scheme":"http://vocabularies.coar-repositories.org/documentation/access_rights/"},"container":{"name":"Microchimica Acta","issnPrinted":"0026-3672","issnOnline":"1436-5073","issnLinking":null,"ep":null,"iss":null,"sp":null,"vol":"191","edition":null,"conferencePlace":null,"conferenceDate":null},"documentationUrls":null,"codeRepositoryUrl":null,"programmingLanguage":null,"contactPeople":null,"contactGroups":null,"tools":null,"size":null,"version":null,"geoLocations":null,"id":"doi_dedup___::cdf1d29a42425b35d41de6cfb52ee175","originalIds":["6228","10.1007/s00604-024-06228-0","50|doiboost____|cdf1d29a42425b35d41de6cfb52ee175","od_______267::bd6940aa20f59405cf378b310dbd4c5f","38353782","PMC10867064","oai:pubmedcentral.nih.gov:10867064","50|od_______267::bd6940aa20f59405cf378b310dbd4c5f","50|od______9436::e472cdb6f77a1a1437ea1bfb7b2edd47","oai:acikerisim.ege.edu.tr:11454/104841"],"pids":[{"scheme":"doi","value":"10.1007/s00604-024-06228-0"},{"scheme":"pmid","value":"38353782"},{"scheme":"pmc","value":"PMC10867064"},{"scheme":"handle","value":"11454/104841"}],"dateOfCollection":null,"lastUpdateTimeStamp":null,"indicators":{"citationImpact":{"citationCount":7,"influence":2.7335119e-9,"popularity":7.869853e-9,"impulse":7,"citationClass":"C5","influenceClass":"C5","impulseClass":"C4","popularityClass":"C4"}},"instances":[{"pids":[{"scheme":"doi","value":"10.1007/s00604-024-06228-0"}],"license":"CC BY","type":"Article","urls":["https://doi.org/10.1007/s00604-024-06228-0"],"publicationDate":"2024-02-14","refereed":"peerReviewed"},{"pids":[{"scheme":"pmid","value":"38353782"},{"scheme":"pmc","value":"PMC10867064"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1007/s00604-024-06228-0"}],"type":"Article","urls":["https://pubmed.ncbi.nlm.nih.gov/38353782"],"publicationDate":"2024-02-15","refereed":"nonPeerReviewed"},{"alternateIdentifiers":[{"scheme":"doi","value":"10.1007/s00604-024-06228-0"}],"license":"CC BY","type":"Other literature type","urls":["http://dx.doi.org/10.1007/s00604-024-06228-0"],"publicationDate":"2024-02-14","refereed":"nonPeerReviewed"},{"pids":[{"scheme":"handle","value":"11454/104841"}],"alternateIdentifiers":[{"scheme":"doi","value":"10.1007/s00604-024-06228-0"}],"type":"Article","urls":["https://hdl.handle.net/11454/104841","https://doi.org/10.1007/s00604-024-06228-0"],"publicationDate":"2024-08-31","refereed":"nonPeerReviewed"}],"isGreen":true,"isInDiamondJournal":false}
local.import.sourceOpenAire
local.indexed.atWOS
local.indexed.atScopus
local.indexed.atPubMed

Dosyalar

Koleksiyonlar